Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

GTH - Genetron Holdings Ltd

Close
4.02
4.020   100.000%

Share volume: 0
Last Updated: Thu 28 Mar 2024 08:03:46 PM CET
Medical Laboratories : -3.31%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
29%
Profitability 25%
Dept financing 26%
Liquidity 68%
Performance 25%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
9.38%
2 Year
346.68%
Key data
Stock price
$4.02
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$3.68 - $4.05
52 WEEK CHANGE
$9.38
MARKET CAP 
82.403 M
YIELD 
N/A
SHARES OUTSTANDING 
91.549 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.34
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Si Z. Wang
Region: US
Website: genetronhealth.com
Employees: 1,150
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Medical Laboratories
Sector: Health Care and Social Assistance

Genetron Holdings Limited engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay.

Recent news